References
- Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, Hua F. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. InMAbs 2016 Aug 17 (Vol. 8, No. 6, pp. 1064-1078). Taylor & Francis.
- Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, Hua F. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. InMAbs 2016 Aug 17 (Vol. 8, No. 6, pp. 1064-1078). Taylor & Francis.
- Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, Berkhout J. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. InMAbs 2018 Jul 4 (Vol. 10, No. 5, pp. 751-764). Taylor & Francis.
- Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacology research & perspectives. 2019 Dec;7(6):e00535.
- Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?. InMAbs 2011 Jan 1 (Vol. 3, No. 1, pp. 61-66). Taylor & Francis.
- Haraya K, Tachibana T, Nezu J. Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metabolism and Pharmacokinetics. 2017 Aug 1;32(4):208-17.
- Haraya K, Tachibana T. Translational approach for predicting human pharmacokinetics of engineered therapeutic monoclonal antibodies with increased FcRn-binding mutations. BioDrugs. 2023 Jan;37(1):99-108.
- Hernandez I, Bott SW, Patel AA, Wolf CG, Hospodar AR, Sampathkumar S, Shrank WH. Pricing of monoclonal antibody therapies: higher if used for cancer. Am J Manag Care. 2018 Feb 1;24(2):109-12.
- Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, Hutton J, Altman DG. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PloS one. 2009 Nov 30;4(11):e7824.
- Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. The Journal of Clinical Pharmacology. 2009 Dec;49(12):1382-402.
- Liu S, Verma A, Kettenberger H, Richter WF, Shah DK. Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. InMAbs 2021 Jan 1 (Vol. 13, No. 1, p. 1993769). Taylor & Francis.
- Oitate M, Masubuchi N, Ito T, Yabe Y, Karibe T, Aoki T, Murayama N, Kurihara A, Okudaira N, Izumi T. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug metabolism and pharmacokinetics. 2011;26(4):423-30.
- Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Journal of Cerebral Blood Flow & Metabolism. 2020 Sep;40(9):1769-77.
- Wang L, Qiang W, Cheng Z. Allometric scaling of therapeutic monoclonal antibodies using antigen concentration as a correction factor: application to the human clearance prediction. Journal of Pharmaceutical Sciences. 2016 Mar 1;105(3):1335-40.
- Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. Jama. 2020 Mar 3;323(9):844-53.